Ribaldone, D.G.; Tribocco, E.; Rosso, C.; Armandi, A.; Vernero, M.; Bugianesi, E.; Astegiano, M.; Saracco, G.M.; Caviglia, G.P.
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study. J. Clin. Med. 2021, 10, 3387.
https://doi.org/10.3390/jcm10153387
AMA Style
Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP.
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study. Journal of Clinical Medicine. 2021; 10(15):3387.
https://doi.org/10.3390/jcm10153387
Chicago/Turabian Style
Ribaldone, Davide Giuseppe, Elisa Tribocco, Chiara Rosso, Angelo Armandi, Marta Vernero, Elisabetta Bugianesi, Marco Astegiano, Giorgio Maria Saracco, and Gian Paolo Caviglia.
2021. "Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study" Journal of Clinical Medicine 10, no. 15: 3387.
https://doi.org/10.3390/jcm10153387
APA Style
Ribaldone, D. G., Tribocco, E., Rosso, C., Armandi, A., Vernero, M., Bugianesi, E., Astegiano, M., Saracco, G. M., & Caviglia, G. P.
(2021). Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study. Journal of Clinical Medicine, 10(15), 3387.
https://doi.org/10.3390/jcm10153387
